Terran Biosciences Receives FDA Clearance for NM-101, the industry’s first software for the analysis of neuromelanin-sensitive MRI The post Terran Biosciences...
Welcome to the News You Might Have Missed, a weekly roundup of psychedelic medicine news to help you catch up and stay informed The post News...
Numinus Wellness Inc. (“Numinus” or the “Company”) (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing traditional and innovative...
Big news as the trial met its primary endpoint, with 50% clinical remission rate at Week 4. The post MindMed Announces Positive Results from Phase 2b...
With only a few weeks left in the year, concern was rising over why MAPS PBC hadn’t yet submitted its NDA. All that, however, was put...
A Seattle doctor is not giving up when it comes to the rescheduling of psilocybin. While the focus on rescheduling cannabis is talked about constantly,...
One in seven Canadian veterans is living with PTSD. Developing a psychedelics research program for veterans should be a public health priority.
MAPS Public Benefit Corporation (“MAPS PBC”), a clinical-stage company dedicated to changing the way mental health conditions are treated, announced...
The FDA has 60 days to decide if the application will be accepted for review. The post MAPS Submits New Drug Application to FDA for MDMA...
Historic filing marks first New Drug Application submission for any psychedelic-assisted therapy. The post Breaking News: MAPS Files New Drug Application...